New York Approves Foundation Medicine to Offer Cancer Sequencing Tests | GenomeWeb

NEW YORK (GenomeWeb) – The New York State Department of Health has given its approval to Foundation Medicine to perform its FoundationOne and FoundationOne Heme tests on residents of New York State.

FoundationOne is a targeted genomic sequencing test for solid tumors that profiles the coding regions of 236 cancer-related genes, as well as 47 introns from 19 other genes for alterations associated with existing and experimental molecularly targeted therapies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: sequencing technique to uncover plant disease-resistance genes, and more.

In a Science Translational Medicine opinion piece, a Merck executive suggests that universities offer money-back guarantees on their research.

NantKwest's Patrick Soon-Shiong received some $148 million in compensation in 2015.

With sequencing moving toward applications, Illumina CEO Francis deSouza says his company has even more to offer, Fast Company reports.